This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background The significance of stress-test induced arrhythmias has been examined in prior studies, but there is no clear consensus regarding its significance. Objectives To determine the significance of stress test-induced arrhythmias. Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023.
Greetings! Welcome to the Physiology Friday newsletter. Details about the sponsors of this newsletter including FSTFUEL electrolytes, Examine.com , and my book “VO2 Max Essentials ” can be found at the end of the post. You can find more products I’m affiliated with on my website. Physiologically Speaking is a reader-supported publication.
tim.hodson Fri, 03/28/2025 - 15:23 Mar. 28, 2025 At theAmerican College of Cardiology (ACC) 2025 meeting,GE HealthCare will introduce RevolutionVibe, i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries.
ST-elevation myocardial infarction (STEMI) is a critical cardiovascular emergency characterized by acute coronary artery occlusion and subsequent myocardial injury. The current standard of care is primary percutaneous coronary intervention (PPCI), which aims to rapidly restore epicardial blood flow. However, despite successful revascularization, microvascular obstruction (MVO) remains a major challenge, contributing to adverse clinical outcomes.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Background High-sensitivity cardiac troponin tests have enhanced early myocardial infarction diagnosis, yet many patients still land in the observe zone (OZ). Guidelines suggest a 3-hour troponin measurement for those in the European Society of Cardiology (ESC) 0/1 hour-algorithm’s OZ, but evidence on extended troponin testing times and their impact on diagnostic accuracy and outcomes remains sparse.
IntroductionHeart failure (HF) causes high symptom burden and shortens life expectancy. Implementation of Palliative Care (PC) concurrently with cardiologic guidelines-directed medical therapy (GDMT) improves quality-of-life (QoL) more than disease-oriented management alone but is underused. To facilitate provision of PC for people living with HF, the Swiss Society of Cardiology (SSC) and the Swiss Society for Palliative Care (palliative.ch) have created joint working-group.MethodsDyads represen
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance patient safety.
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance patient safety.
BackgroundThere is a growing body of evidence indicating that metabolites are associated with an increased risk of cardiovascular diseases (CVDs), the underlying causality of these associations remains largely unchallenged. Given the inherent difficulty in establishing causality using epidemiological data, we employed the technique of Mendelian randomization to investigate the potential role of plasma metabolite factors in influencing the risk of CVDs.MethodsThe exposure was based on 1,400 plasm
Background Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome in which signs and symptoms of heart failure (HF) occur despite a normal left ventricular ejection fraction. Transthoracic echocardiography (TTE) is the first-line imaging modality but disparities in patient pathways across the UK can lead to delayed diagnosis and treatment.
Experts discuss the long-term efficacy and safety of abrocitinib and upadacitinib in atopic dermatitis (AD), with sustained monotherapy results showing significant improvements in Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Validated IGA-AD (vIGA-AD) scores. They also consider the safety profiles and potential risks, particularly in older patients, for long-term use of JAK inhibitors.
IntroductionVentricular septal defect (VSD) is a common congenital heart disease (CHD), accounting for 2030% of all CHD cases. While surgical closure has been the gold standard for treatment, transcatheter closure has emerged as a less invasive alternative, particularly for perimembranous VSDs. This study aimed to evaluate the early and mid-term outcomes of transcatheter closure using a double-disc occluder device in a single-center Vietnamese cohort.MethodA prospective descriptive study was con
Founded in 1984, Casslings mission is to strengthen community healthcare. The company strives to bring innovative imaging solutions to communities and providers, so that patients and their families can live their best life. Thats why Cassling is excited to introduce a new awards program that recognizes and celebrates imaging teams contributions to keeping care local and improving patient outcomes.
Sad news travels fast. The Boston cardiology community learned very quickly about the passing of David Casavant. David died suddenly at his home on a Friday a few weeks ago. Suddenly, David was gone; his death was unexpected, too early and too sad. What a tremendous loss. Our companion, our friend, now gone. The old Boston Pacing Clubour friends and colleagues in electrophysiology, caring for patients, fighting for innovation, pushing new horizons, bouncing new ideas, and trying something neware
The risk of a full-blown stroke will remain high for at least a decade after a person has a slight brush with stroke, in the form of a transient ischemic attack or minor stroke, a new study says.
Chronic ventricular pacing (VP) in the Fontan population is associated with adverse outcomes. Two studies evaluated risk factors for adverse outcomes related to VP. Chubb etal1 reported risk factors for a primary end point of death or transplant attributable to VP in an international multicenter, retrospective, case-control study. They compared 213 patients after Fontan with VP with matched controls and found a 4.6 times higher risk of the primary end point in the VP cohort, occurring in 22% at
The MADIT trial1 conducted between 1991 and 1996 was the first trial testing primary prevention of mortality with an implantable cardioverter-defibrillator (ICD). The study enrolled 196 patients randomized 1:1 to ICD vs no ICD and reported a 56% improvement in survival with an ICD in patients with coronary heart disease, reduced ventricular function, nonsustained ventricular tachycardia (VT), and inducible VT.
(MedPage Today) -- Education level was associated with the trajectory of cognitive decline following stroke, an individual participant data meta-analysis of four U.S. cohort studies showed. After adjusting for pre-stroke cognition, college-educated.
The implantable cardioverter-defibrillator (ICD) remains one of the most effective therapies for preventing sudden cardiac death (SCD). Data supporting the role of primary prevention ICDs in patients with heart failure were generated by rigorous randomized controlled trials (RCTs).1 Those data have informed professional guidelines and clinical practice for the past two and a half decades.1 During this time period, numerous advances in ICD technology, care, and follow-up have resulted in unequivo
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial examines the efficacy and safety of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction according to the presence and type of atrial fibrillation.
Advocacy is one of the key foundational missions of Heart Rhythm Society (HRS). Since its inception, HRS and its predecessor organizations have been able to provide the electrophysiology (EP) community the much needed assistance in various aspects of their professional activities. These efforts ranged from obtaining new codes for various procedures and aiding the American Medical Association in determining the appropriate value for these procedures.
Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.
In a trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events.
To evaluate the efficacy of anti-CD3 monoclonal antibody (mAb) in patients with type 1 diabetes (T1D) and identify the influencing factors. Randomized controlled trials comparing anti-CD3 mAb with placebo or standard care in T1D participants were screened from PubMed, Embase, and Cochrane databases until 31 May 2024. Changes in area under the curve (AUC) of C-peptide, HbA1c level and daily insulin requirement were main outcomes.
A 2024 survey finds that most healthcare providers believe quality of life should be considered as much as symptom control when managing bipolar I disorder and schizophrenia.
Myocardial fibrosis is a critical link in preventing the progression of heart disease. This study conducted a bibliometric analysis of its mechanism to identify trends and hotspots, aiming to provide valuable.
These findings result from a systematic review and meta-analysis looking at the utilization of dupilumab among children and adolescents with atopic dermatitis.
The effect of cadmium exposure on mortality risk among individuals with diabetes and prediabetes remains unclear, particularly regarding potential mediation by oxidative stress and inflammation. This study aim.
The Cardiovascular-Kidney-Metabolic (CKM) syndrome underscores the complex interactions among metabolic disorders, kidney disease, and cardiovascular conditions. Insulin resistance (IR) and inflammation are cr.
I saw two patients recently, with a similar degree of hypertension and LVH. One with a normal-sized LA and the other with a mild LA enlargement. When checked for the “E” declaration time, it was found to be absolutely normal in the patient who had LAE. The one with normal LA size had a relatively short DT and his functional capacity was less. 52-year-old man with HT, and LVH with mild LAE.
On Match Day, the 2025 Residency Match saw record participation with a 4.7% increase in applicants, and thoracic & vascular surgery reached a historic 100% fill rate.
A panelist discusses how they've tried various treatments for alopecia areata, including topical corticosteroids, intralesional steroid injections, immunotherapy, and Janus kinase inhibitors, with varying degrees of success in managing their condition, from temporary partial regrowth to more substantial and sustained hair restoration with newer targeted therapies.
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
64 
Let's personalize your content